• Protocols

• A032103

  OPEN TO ACCRUAL

  Ph 2 and 3 Nivolumab with or without Relatlimab in adjuvant urothelial cancer
  
  

• INT22-09-01

  OPEN TO ACCRUAL

  A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
  
  

• UW26056

  OPEN TO ACCRUAL

  Ph 2 Enfortumab + Pembro for Bladder Preservation in MIBC Participants